AGE
Income statement / Annual
Last year (2024), AgeX Therapeutics, Inc.'s total revenue was $56.00 K,
a decrease of 60.56% from the previous year.
In 2024, AgeX Therapeutics, Inc.'s net income was -$11.14 M.
See AgeX Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$56.00 K |
$142.00 K |
$34.00 K |
$144.00 K |
$1.87 M |
$1.73 M |
$1.40 M |
$1.40 M |
| Cost of Revenue |
$0.00
|
$171.00 K
|
$13.00 K
|
$19.00 K
|
$158.00 K
|
$244.00 K
|
$364.00 K
|
$168.00 K
|
| Gross Profit |
$0.00
|
-$29.00 K
|
$21.00 K
|
$125.00 K
|
$1.71 M
|
$1.48 M
|
$1.03 M
|
$1.24 M
|
| Gross Profit Ratio |
0
|
-0.2
|
0.62
|
0.87
|
0.92
|
0.86
|
0.74
|
0.88
|
| Research and Development Expenses |
$7.48 M
|
$603.00 K
|
$1.03 M
|
$1.46 M
|
$4.98 M
|
$5.90 M
|
$6.63 M
|
$5.78 M
|
| General & Administrative Expenses |
$9.62 M
|
$9.33 M
|
$5.97 M
|
$6.71 M
|
$7.40 M
|
$8.14 M
|
$5.65 M
|
$3.87 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.62 M
|
$9.33 M
|
$5.97 M
|
$6.71 M
|
$7.40 M
|
$8.14 M
|
$5.65 M
|
$3.87 M
|
| Other Expenses |
$0.00
|
$11.00 K
|
$13.00 K
|
$0.00
|
$44.00 K
|
$0.00
|
$0.00
|
$38.00 K
|
| Operating Expenses |
$17.10 M
|
$9.93 M
|
$7.00 M
|
$8.16 M
|
$12.38 M
|
$14.04 M
|
$12.28 M
|
$9.65 M
|
| Cost And Expenses |
$0.00
|
$10.10 M
|
$7.01 M
|
$8.18 M
|
$12.54 M
|
$14.29 M
|
$12.64 M
|
$9.82 M
|
| Interest Income |
$0.00
|
$0.00
|
$3.34 M
|
$1.10 M
|
$404.00 K
|
$29.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
-$526.00 K
|
$4.90 M
|
$3.34 M
|
$1.10 M
|
$0.00
|
$0.00
|
$116.00 K
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$131.00 K
|
$145.00 K
|
$579.00 K
|
$1.68 M
|
$951.00 K
|
$535.00 K
|
$682.00 K
|
| EBITDA |
-$17.05 M |
-$9.71 M |
-$7.04 M |
-$7.93 M |
-$8.81 M |
-$11.61 M |
-$10.71 M |
-$9.49 M |
| EBITDA Ratio |
-304.43
|
-68.36
|
-207.12
|
-55.09
|
-4.72
|
-6.72
|
-7.67
|
-6.76
|
| Operating Income Ratio |
-304.43
|
-70.14
|
-205.15
|
-55.83
|
-5.71
|
-7.27
|
-8.06
|
-4.75
|
| Total Other Income/Expenses Net |
$5.91 M
|
-$4.85 M
|
-$3.55 M
|
-$649.00 K
|
$272.00 K
|
$323.00 K
|
$3.51 M
|
$1.78 M
|
| Income Before Tax |
-$11.14 M
|
-$14.81 M
|
-$10.52 M
|
-$8.58 M
|
-$11.13 M
|
-$12.24 M
|
-$7.73 M
|
-$6.64 M
|
| Income Before Tax Ratio |
-198.95
|
-104.3
|
-309.47
|
-59.6
|
-5.96
|
-7.08
|
-5.54
|
-4.73
|
| Income Tax Expense |
$0.00
|
-$8.00 K
|
$152.00 K
|
$1.64 M
|
-$150.00 K
|
$148.00 K
|
$3.51 M
|
-$1.80 M
|
| Net Income |
-$11.14 M
|
-$14.80 M
|
-$10.67 M
|
-$10.22 M
|
-$10.98 M
|
-$12.38 M
|
-$7.50 M
|
-$6.58 M
|
| Net Income Ratio |
-198.95
|
-104.25
|
-313.94
|
-70.97
|
-5.88
|
-7.17
|
-5.37
|
-4.69
|
| EPS |
-1.51 |
-13.72 |
-9.89 |
-9.49 |
-10.25 |
-11.69 |
-7.56 |
-6.46 |
| EPS Diluted |
-1.51 |
-13.72 |
-9.89 |
-9.49 |
-10.25 |
-11.69 |
-7.56 |
-6.46 |
| Weighted Average Shares Out |
$7.36 M
|
$1.08 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992.72 K
|
$1.02 M
|
| Weighted Average Shares Out Diluted |
$7.36 M
|
$1.08 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992.72 K
|
$1.02 M
|
| Link |
|
|
|
|
|
|
|
|
